Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cadrenal Therapeutics, Inc. - Common Stock
(NQ:
CVKD
)
8.530
+0.360 (+4.41%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cadrenal Therapeutics, Inc. - Common Stock
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
December 30, 2025
Via
ACCESS Newswire
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
December 29, 2025
Via
ACCESS Newswire
Cadrenal's Quiet Expansion Play Is Starting to Get Loud
December 12, 2025
Via
ACCESS Newswire
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
December 12, 2025
Via
ACCESS Newswire
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
August 05, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
June 12, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
June 04, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
May 15, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
May 13, 2025
Via
Get News
Topics
Death
Economy
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
May 08, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
April 03, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
March 13, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
March 04, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
February 06, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
February 05, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 09, 2025
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
December 31, 2024
From
Cadrenal Therapeutics
Via
Business Wire
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
December 18, 2024
From
Cadrenal Therapeutics, Inc.
Via
Business Wire
Sidoti Events, LLC's Virtual August Micro-Cap Conference
August 13, 2024
Via
ACCESSWIRE
Cadrenal Therapeutics Inc. (NASDAQ: CVKD) Featured in Coverage of NobleCon19
December 05, 2023
Via
Investor Brand Network
Topics
Death
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
